These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 37762787)

  • 1. Severe Asthma and Biological Therapies: Now and the Future.
    Sardon-Prado O; Diaz-Garcia C; Corcuera-Elosegui P; Korta-Murua J; Valverde-Molina J; Sanchez-Solis M
    J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma.
    Porsbjerg CM; Menzies-Gow AN; Tran TN; Murray RB; Unni B; Audrey Ang SL; Alacqua M; Al-Ahmad M; Al-Lehebi R; Altraja A; Belevskiy AS; Björnsdóttir US; Bourdin A; Busby J; Canonica GW; Christoff GC; Cosio BG; Costello RW; FitzGerald JM; Fonseca JA; Hansen S; Heaney LG; Heffler E; Hew M; Iwanaga T; Jackson DJ; Kocks JWH; Kallieri M; Bruce Ko HK; Koh MS; Larenas-Linnemann D; Lehtimäki LA; Loukides S; Lugogo N; Maspero J; Papaioannou AI; Perez-de-Llano L; Pitrez PM; Popov TA; Rasmussen LM; Rhee CK; Sadatsafavi M; Schmid J; Siddiqui S; Taillé C; Taube C; Torres-Duque CA; Ulrik C; Upham JW; Wang E; Wechsler ME; Bulathsinhala L; Carter V; Chaudhry I; Eleangovan N; Hosseini N; Rowlands MA; Price DB; van Boven JFM
    J Allergy Clin Immunol Pract; 2022 May; 10(5):1202-1216.e23. PubMed ID: 34990866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach.
    López-Viña A; Díaz Campos RM; Trisan Alonso A; Melero Moreno C
    Front Allergy; 2022; 3():1007593. PubMed ID: 36452259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biologics in severe childhood asthma].
    Amat F
    Rev Mal Respir; 2023 Oct; 40(8):675-683. PubMed ID: 37749027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab.
    Cheng SL
    Life (Basel); 2021 Jul; 11(8):. PubMed ID: 34440488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologics to Treat Severe Asthma in Children and Adolescents: A Practical Update.
    Marseglia GL; Licari A; Tosca MA; Ciprandi G
    Pediatr Allergy Immunol Pulmonol; 2020 Dec; 33(4):168-176. PubMed ID: 35921565
    [No Abstract]   [Full Text] [Related]  

  • 8. The Current State of Biologic Therapies for Treatment of Refractory Asthma.
    Mavissakalian M; Brady S
    Clin Rev Allergy Immunol; 2020 Oct; 59(2):195-207. PubMed ID: 31981048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic Therapies in Pediatric Asthma.
    Perikleous EP; Steiropoulos P; Nena E; Paraskakis E
    J Pers Med; 2022 Jun; 12(6):. PubMed ID: 35743783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
    Giovannini M; Mori F; Barni S; de Martino M; Novembre E
    Ital J Pediatr; 2019 Nov; 45(1):151. PubMed ID: 31779657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Targets for Biological Therapies of Severe Asthma.
    Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
    Front Immunol; 2020; 11():603312. PubMed ID: 33329598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab.
    Li L; Wang Z; Cui L; Xu Y; Guan K; Zhao B
    Clin Transl Allergy; 2021 Jun; 11(4):e12038. PubMed ID: 34123366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matching-adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics.
    Bourdin A; Husereau D; Molinari N; Golam S; Siddiqui MK; Lindner L; Xu X
    Clin Exp Allergy; 2020 Apr; 50(4):442-452. PubMed ID: 31943429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologicals in the Treatment of Pediatric Atopic Diseases.
    Vom Hove M; Neininger MP; Bertsche T; Prenzel F
    Handb Exp Pharmacol; 2020; 261():131-151. PubMed ID: 32076895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives.
    Licari A; Manti S; Castagnoli R; Parisi GF; Salpietro C; Leonardi S; Marseglia GL
    Paediatr Drugs; 2019 Aug; 21(4):215-237. PubMed ID: 31325115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Rocha C; Beltran J; Song Y; Posso M; Solà I; Alonso-Coello P; Akdis C; Akdis M; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Martín IH; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Quirce S; Sastre J; Shamji M; Schwarze J; Canelo-Aybar C; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1043-1057. PubMed ID: 32064642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologics in severe asthma.
    Pelaia C; Pelaia G; Crimi C; Longhini F; Lombardo N; Savino R; Sciacqua A; Vatrella A
    Minerva Med; 2022 Feb; 113(1):51-62. PubMed ID: 33555158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe asthma in children: Current goals and unmet needs.
    Licari A; Manti S; Chiappini E; Ciprandi G; Marseglia GL
    Pediatr Allergy Immunol; 2020 Feb; 31 Suppl 24():40-42. PubMed ID: 32017220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New perspectives of childhood asthma treatment with biologics.
    Just J; Deschildre A; Lejeune S; Amat F
    Pediatr Allergy Immunol; 2019 Mar; 30(2):159-171. PubMed ID: 30444939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-Life Effectiveness of Benralizumab, Mepolizumab and Omalizumab in Severe Allergic Asthma Associated with Nasal Polyps.
    Tiotiu A; Mendez-Brea P; Ioan I; Romero-Fernandez R; Oster JP; Hoang TC; Roux P; Ochoa-Gutierrez DC; Bonniaud P; de Blay F; Gonzalez-Barcala FJ
    Clin Rev Allergy Immunol; 2023 Apr; 64(2):179-192. PubMed ID: 35420388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.